APLT Investor Alert: Robbins LLP Reminds Stockholders of - GlobeNewswire
Robbins LLP investigates Applied Therapeutics, Inc. (APLT) for misleading investors about its lead drug candidate, govorestat, during Jan 3, 2024 - Dec 2, 2024. The company received a Complete Response Letter (CRL) from the FDA on Nov 27, 2024, causing a stock decline of over 80%. On Dec 2, 2024, Applied Therapeutics disclosed a 'warning letter' from the FDA regarding clinical trial issues.
Highlighted Terms
Related News
Robbins LLP investigates Applied Therapeutics, Inc. (APLT) for misleading investors about its lead drug candidate, govorestat, during Jan 3, 2024 - Dec 2, 2024. The company received a Complete Response Letter (CRL) from the FDA on Nov 27, 2024, causing a stock decline of over 80%. On Dec 2, 2024, Applied Therapeutics disclosed a 'warning letter' from the FDA regarding clinical trial issues.